## WHAT IS CLAIMED IS:

5

15

20

1. An isolated, recombinant t polypeptide molecule comprising a first amino acid sequence which is a fragment of a native proteolipid protein having a wild type or mutant sequence as compared with the native sequence of said proteolipid protein, and optionally comprising a second amino acid sequence fused in frame thereto to create a fusion polypeptide, which first polypeptide is encoded by an mRNA having an Internal Ribosome Entry Site ((IRES) wherein translation of the mRNA initiates at said IRES, such that the N-terminal amino acid residue of said first polypeptide corresponds to an internal residue of said proteolipid protein.

- 10 2. The polypeptide of claim 1 or wherein the proteolipid protein is human PLP/DM20.
  - 3. The first polypeptide or of claim 1 selected from the group consisting of:
  - (a) PIRP-M, having the amino acid sequence SEQ ID NO:6;
  - (b) PIRP-L, having the amino acid sequence SEQ ID NO:8;
    - (c) a fusion polypeptide of (a) or (b) wherein said second amino acid sequence encodes a naturally fluorescent protein or peptide;
    - (d) a His-tagged fusion polypeptide of PIRP-M having the amino acid sequence SEQ ID NO:12;
    - (e) a His-tagged fusion polypeptide of PIRP-L having the amino acid sequence SEQ ID NO:16; and
    - (f) PIRP-J having a mutant sequence compared to said proteolipid protein, the sequence of said PIRP-J being SEQ ID NO:18, or a human homologue thereof.
  - 4. The polypeptide of claim 3 which is PIRP-M having the amino acid sequence SEQ ID NO:6
  - 5. The polypeptide of claim 3 which is PIRP-L, having the amino acid sequence SEQ ID NO:8.
  - 6. The polypeptide of claim 3 which is PIRP-J having the amino acid sequence SEQ ID NO:18.
- 7. The fusion polypeptide of claim 3 wherein said fluorescent protein is yellow or green green fluorescent protein (GFP) or a fluorescent homologue thereof.
  - 8. The His-tagged fusion polypeptide of claim 3 having the sequence SEQ ID NO:12.
  - 9. The His-tagged fusion polypeptide of claim 3 having the sequence SEQ ID NO:16.
- 10. An isolated nucleic acid encoding the polypeptide of claim 1, the mutant sequence thereof, or the fusion polypeptide thereof.

- 11. The nucleic acid of claim 10 which is a DNA molecule.
- 12. The nucleic acid of claim 10 which is an RNA molecule.
- 13. The nucleic acid of claim 10 wherein the proteolipid protein is human PLP/DM20.
- 14. The nucleic acid of claim 10 encoding a polypeptide or fusion polypeptide selected from the group consisting of:
  - (a) PIRP-M, having the amino acid sequence SEQ ID NO:6;
  - (b) PIRP-L, having the amino acid sequence SEQ ID NO:8;

10

15

- (c) a fusion polypeptide of (a) or (b) wherein said second amino acid sequence encodes a naturally fluorescent protein or peptide;
- (d) a His-tagged fusion polypeptide of PRP-M having the amino acid sequence SEQ ID NO:12;
- (e) a His-tagged fusion polypeptide of PIRP-L having the amino acid sequence SEQ ID NO:16; and
- (f) PIRP-J having a mutant sequence compared to said proteolipid protein, the sequence of said PIRP-J being SEQ ID NO:18, or a human homologue thereof.
- 15. The nucleic acid of claim 14 which encodes PIRP-M and has a nucleotide sequence SEQ ID NO:5 or SEQ ID NO:9.
- 16. The nucleic acid of claim 14 which encodes PIRP-L and has a nucleotide sequence SEQ ID NO:7 or SEQ ID NO:13.
- 20 17. The nucleic acid of claim 14 which encodes PIRP-J and has a nucleotide sequence SEQ ID NO:17.
  - 18. The nucleic acid of claim 14 which encodes said His-tagged fusion polypeptide of PIRP-M, which nucleic acid has a nucleotide sequence SEQ ID NO:11;
- 19. The nucleic acid of claim 14 which encodes said His-tagged fusion polypeptide of PIRP-L, which nucleic acid has a nucleotide sequence SEQ ID NO:15;
  - 20. The nucleic acid of claim 14 which encodes said fusion polypeptide wherein said second amino acid sequence encodes a naturally fluorescent protein or peptide.
  - 21. The nucleic acid of claim 20 wherein said fluorescent protein is yellow or green green fluorescent protein (GFP) or a fluorescent homologue thereof.
- The nucleic acid molecule of any of claims 10-21 operatively linked to a promoter.

23. The nucleic acid molecule of claim 22, wherein the promoter is one which is expressed in a mammalian cell.

- 24. The nucleic acid molecule of claim 23 wherein said mammalian cell is a neuronal cell, a glial cell or a stem cell.
- 5 25. The nucleic acid molecule of claim 24 wherein said glial cell is an oligodendrocyte.
  - 26. The nucleic acid molecule of claim 24 wherein the stem cell is a neural stem cell, an oligodendrocyte progenitor cell, an embryonic stem cell or a hemopoietic stem cell.
  - 27. A vector comprising the nucleic acid of any of claims 10-21.
  - 28. The vector of claim 27, selected from the group consisting of PLP-GFP/DM20-GFP;
- PLP-GFP/DM20-GFP Tet-On; PLP-GFP/DM20-GFP M1L; PLP-GFP/DM20-GFP M1L/M205L;
  PLP-GFP/DM20-GFP M1L/M234L; PLP-GFP/DM20-GFP M1L/M205L/M234L; PLP-GFP/DM20-GFP Pro-; JPLP-GFP/JDM20-GFP, JPLP-GFP/JDM20-GFP M1L; JPLP-GFP/JDM20-GFP M1L/M205L;
  RshPLP-GFP/RshDM20-GFP M1L; PLP-GFP/DM20-GFP M1L/K268R;
  PLP-GFP/DM20-GFP M1L/K275R; PLP-GFP/DM20-GFP M1L/K268R/K275R; and
- 15 PLP-GFP/DM20-GFP M1L/R272K

20

- 29. An expression vector or cassette comprising the nucleic acid of any of claims 10-21 operatively linked to
  - (a) a promoter; and
  - (b) optionally, additional regulatory sequences that regulate expression of said nucleic acid in a eukaryotic cell.
- 30. The expression vector or cassette of claim 27 comprising a vector selected from the group consisting of pCMV; pEGFP-N1; pEYFP-N1; pEGFP-Tet-On; pBluescript II KS+; and pET-14b.
- 31. The expression vector or cassette of claim 28 elected from the group consisting of 205M25 CMV/234M-CMV; 205M-His-CMV/234M-His-CMV; 205M-BsKS+/234M-BsKS+; 205M-His-BsKS+/
  234M-His-BsKS+; and 205M-ET-14b/234M-ET-14b.
  - 32. A cell which has been modified to comprise the nucleic acid of any of claims 10-21.
  - 33. The cell of claim 32 which is a mammalian cell.
- 30 34. A cell which has been modified to comprise the vector of claim 27.

35. A cell which has been modified to comprise the vector or expression cassette of claim 31.

- 36. The cell of claim 35 which expresses said nucleic acid molecule.
- 37. The cell of claim 36 which is mammalian cell
- 38, The cell of claim 37 wherein said mammalian cell is a neuronal cell, a glial cell or a stem cell.
- 5 39. The cell of claim 38 wherein said glial cell is an oligodendrocyte.
  - 40.. The cells of claim 38 wherein the stem cell is a neural stem cell, an oligodendrocyte progenitor cell, an embryonic stem cell or a hemopoietic stem cell.
  - 41. A pharmaceutical composition, comprising:
    - (a) pharmaceutically acceptable excipient in combination with
- 10 (b) the polypeptide of any of claims 1-6.

15

- 42. A pharmaceutical composition, comprising:
  - (a) pharmaceutically acceptable excipient in combination with
  - (b) the nucleic acid molecule of claims 23.
- 43. A pharmaceutical composition, comprising:
  - (a) pharmaceutically acceptable excipient in combination with
  - (b) the expression vector or cassette of claim 29;
- 44. A pharmaceutical composition, comprising:
  - (a) pharmaceutically acceptable excipient in combination with
  - (b) the cell of claim 33.
- 20 45. A pharmaceutical composition, comprising:
  - (a) pharmaceutically acceptable excipient in combination with
  - (b) the cell of claim 36.